• 03 Oct 2025
• Admin
• News Article

Novartis to launch direct-to-patient platform for Cosentyx in the US

Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa and psoriatic arthritis.?It has been studied clinically for more than 17 years and has been used to treat more than 1.8 million patients globally since its launch in 2015.  

“Breakthrough innovation is what drives us at Novartis, in scientific research, medicine development, and in the ways in which we deliver our innovation to patients. In the US, we have long recognized that we?need new ways to reach patients more directly by removing barriers in the system,” said Victor Bultó, president, US for Novartis. “The launch of this new platform is a first step as we continue to work toward solutions to provide our net prices more directly to patients and make the healthcare system work better for Americans.”

Through the DTP platform, Novartis will offer Cosentyx to American patients at a price that reflects the average savings that insurers and pharmacy benefit managers receive. The Cosentyx DTP platform serves as proof-of-concept for a direct-selling model for specialty medicines and ideally would work alongside insurance to help improve patient affordability. In the US, the company intends to offer a DTP option for additional medicines in its portfolio as appropriate and is exploring a direct-to-business model, selling Cosentyx, and potentially additional medicines, to large employers as another way to increase access and affordability.  

Novartis offers multiple programs to help patients access Cosentyx, with the new DTP platform presenting an additional option. Eligible US Cosentyx patients with commercial insurance may pay as little as $0 for their prescription through one such program. Additionally, eligible commercially insured patients can receive help to investigate their insurance coverage. If they are in the process of appealing an initial denial of coverage, commercially insured patients may also be eligible to receive Cosentyx at no cost for up to two years.   

For patients who cannot afford the cost of their Novartis medication, are uninsured or have government insurance, and meet income guidelines and other eligibility criteria, the Novartis Patient Assistance Foundation, Inc. (NPAF), an independent, 501(c)(3) non-profit entity, provides Cosentyx at no cost.

Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases. It is approved for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and hidradenitis suppurativa (HS), as well as in paediatric patients with PsO, enthesitis-related arthritis (ERA), and juvenile psoriatic arthritis (JPsA). Cosentyx is supported by robust evidence and 10 years of real-world data demonstrating its long-term safety and sustained efficacy. Since its launch in 2015, it has been used to treat more than 1.8 million patients worldwide and is now approved in over 100 countries.